Trial Profile
Immune phenotyping in chronic hepatitis C patients treated with Sofosbuvir and Daclatasvir combination with or without Ribavirin for 12 or 24 weeks -SODA study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Nov 2017
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Pharmacodynamics
- Acronyms SODA
- 01 Oct 2017 Status changed from recruiting to completed, as per the results published in the Antiviral Research
- 29 Aug 2015 New trial record